According to Vision Research Reports, the global acute agitation and aggression treatment market size surpassed US$ 3 Bn in 2019 and is projected to expand US$ 4.5 billion by 2027 with a CAGR of 5.2% from 2020 to 2027.
Increase in the diagnosis of agitation and aggression in psychological illnesses, establishment of organizations to spread awareness, and rise in economic burden of psychological illness contribute to the growth of the global acute agitation and aggression treatment market.
Agitation can be defined as excessive motor or verbal behavior, which can escalate to aggression. Physical agitation and aggression manifest in the form of throwing objects toward people, and verbal agitation and aggression manifest as abuses and threats. Acute agitation and aggression is one of the common symptoms in various mental illnesses, including schizophrenia, dementia, bipolar disorder, alcohol withdrawal, and depression.
Opportunity Analysis for Market Players
As awareness about the condition and its long-term effect increases, there has been an exponential growth in the number of patients receiving medical help for acute agitation and aggression, which has intensified the competitiveness of the landscape. In order to stay ahead of the curve, market players make heavy investments in research & development activities to increase the exclusiveness of their product portfolios, and Ono Pharmaceuticals Co., Ltd has implemented the same strategy. The company inaugurated a new research center for strengthening its development and manufacturing capabilities of novel drugs for the treatment of mental illnesses.
Additionally, in order to introduce novel treatments, research activities on lithium, cannabinoids, analgesics, narcotics, and non-steroidal anti-inflammatory drugs, as well as newer antiepileptic drugs are ongoing at a significant pace. For instance, BXCL501, developed by BioXel Technologies, for the treatment of acute agitation and aggression condition, indicating schizophrenia, bipolar disorder, and geriatric dementia, is a pipeline drug. Another player, H. Lundbeck A/S, accounts for the development of Rexulti, a pipeline drug for the treatment of agitation, indicating dementia.
Since drugs consumed for acute agitation and aggression treatment require a prescription, manufactures can zoom-in their focus on partnerships and collaborations with hospitals, ambulatory surgical centers, and psychiatric care facilities, in order to ensure the long-term supply of drugs. As the Asia Pacific acute agitation and aggression treatment market is catching up with the exponential growth pace of North America, manufacturers can devise a cost-competitive strategy to penetrate into cost-sensitive markets. All-in-all, drug manufacturers can look at steady growth of the acute agitation and aggression treatment market during the forecast period.
Spreading Awareness about Agitation & Aggression and Rise in Economic Burden of Psychological Illness Drive Market
Second-generation Anti-psychotics to Capture Major Market Share
Increase in Prescription of Anti-psychotics to Propel Acute Agitation and Aggression Treatment Market
The Exponentially Growing End User of the Market
Marketing campaigns, as initiated by private companies, and increase in general awareness, as undertaken by central health authorities, regarding acute agitation and aggression treatment, are likely to surge the number of end users in the industry. Currently, hospitals, ambulatory surgical centers, and psychiatric care facilities, among others, account for the massive adoption of drugs and treatment procedures. However, hospital and ambulatory surgical centers show a striking RoI potential with their high concentration in developed countries and even in remote areas of developing countries. Since patients with acute agitation and aggression disorder require immediate attention and care, to further avoid the condition from worsening, intensive care units and emergency departments of hospitals are gaining high traction.
In 2019, hospitals and ambulatory surgical centers collectively accounted for ~45% of the market share, with the growth in the number of individuals seeking screening and treatment for acute agitation and aggression disorder. However, once held back on account of the dearth of skilled psychiatrists, psychiatric care facilities are witnessing exponential improvement in the number of skilled medical personnel as well as patients demanding consultations for acute agitation and aggression treatment. This is likely to stimulate the popularity of psychiatric care facilities, which are projected to record a CAGR of ~5% during the forecast period.
Asia Pacific Market to Expand at Rapid Pace
By Drug Class
By Route of Administration
By End User
Scope of the Study
Vision Research Reports conducted a comprehensive assessment regarding the growth potential of the acute agitation and aggression treatment market, in its latest research report, for the forecast period of 2020-2027. The research report consists of some distinguished insights for stakeholders for them to sustain their position and move to a higher market share. This exclusive research report is intended at providing rare and distinguished insights pertaining to the growth of the acute agitation and aggression treatment market, and offers information regarding the growth opportunities for market players. With the help of the insights mentioned in the research report, stakeholders in the acute agitation and aggression treatment market will be able to gain a brief outlook on its growth trajectory, which can help them in making well-informed strategies for their business growth.
The comprehensive business study analyzes and discusses Porter’s Five Forces, with a latent aim to provide the key growth strategies available in the acute agitation and aggression treatment market during the forecast period. This comprehensive guide provides key insights regarding the competition present in the acute agitation and aggression treatment market by identifying key competitors. This exclusive research report also offers information about the key strategies, financials, and notable developments of the acute agitation and aggression treatment market during the forecast period of 2020-2027. The acute agitation and aggression treatment market assessment has been conducted in terms of value (US$ Mn).
Key Questions Answered
This comprehensive research report analyzes and answers key questions concerning the growth of the acute agitation and aggression treatment market for the forecast period of 2020-2027. Some of the key questions answered in this research report are:
The research undertaken by VRR analysts consists of a robust approach in order to cull key insights regarding the growth of the acute agitation and aggression market for the forecast period of 2020-2027. Interviews as well as discussions with leading opinion leaders, market heads, vendors, distributors, industry experts, and key players were carried out in order to conduct primary research. In addition to this, our analysts also conducted a thorough secondary study of marketing collaterals, industry associations, company websites, and government statistics.